REGN7041

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Active Noninfectious Uveitis Affecting the Posterior SegmentNoninfectious Uveitis

Phase 1

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

TerminatedNCT07218770

Regeneron PharmaceuticalsActive Noninfectious Uveitis Affecting the Posterior Segment

Start: 2025-12-17End: 2026-07-21Updated: 2026-08-17

A Phase 1/2a Study of REGN7041 (anti-CD3 monoclonal antibody) in patients with Active Noninfectious Uveitis affecting the Posterior Segment

Not yet recruitingCTIS2025-521713-57-00

Regeneron Pharmaceuticals Inc.Noninfectious Uveitis

Target: 5Updated: 2026-03-05